AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies
Retrieved on:
Wednesday, September 22, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Infectious Diseases, Clinical Trials, Biotechnology, Infection, Result, Partnership, ABCL, Mattia Trianni, Efficiency, Degenerative disease, Risk, Security (finance), CMC, Private Securities Litigation Reform Act, HKEX, U.S. Securities and Exchange Commission, Conversation, Patient, Financial condition report, CEO, Antibody, Terminology, Disease, Analysis, Technology, Research, Drug development, Nasdaq, Pharmaceutical industry, Vaccine, Everest Medicines, AbCellera Biologics Inc., EVEREST MEDICINES, ABCELLERA BIOLOGICS INC.
AbCellera (Nasdaq: ABCL) and Everest Medicines Limited (HKEX 1952.HK, Everest) announced today that they have entered into a multi-year collaboration and license agreement to discover therapeutic antibodies for up to 10 targets selected by Everest.
Key Points:
- AbCellera (Nasdaq: ABCL) and Everest Medicines Limited (HKEX 1952.HK, Everest) announced today that they have entered into a multi-year collaboration and license agreement to discover therapeutic antibodies for up to 10 targets selected by Everest.
- We are proud to partner with Everest as they build a robust pipeline of innovative medicines for patients in Asia and beyond, said Carl Hansen, Ph.D., CEO and President of AbCellera.
- By partnering with AbCellera, Everest will benefit from an operating system that supports many antibody modalities to unlock new target classes and open new disease areas to therapeutic access.
- Under the terms of the agreement, Everest will have the rights to develop and commercialize antibodies resulting from the collaboration.